Latest Conference Articles

Depemokimab shows significant improvements in asthma symptoms and peak expiratory flow, supporting its twice-yearly use for severe asthma management.

An expert highlights the need for early detection of aortic stenosis symptoms in elderly patients, urging pharmacists and clinicians to monitor subtle changes.

Biykem Bozkurt, MD, PhD, FACC, highlights the need for reliable activity monitoring in heart failure care, addressing challenges of digital wearables in clinical practice.

The Annual Meeting Highlighted Emerging Research on Hormone Therapy, Brain and Heart Health, Disparities in Menopause Care, and the Expanding Role of Pharmacists

New research reveals GLP-1 receptor agonists like semaglutide offer heart failure benefits beyond weight loss, emphasizing pharmacists' crucial role in patient care.

Pharmacists play a crucial role in holistic healthcare, enhancing patient care through education and collaboration with allied health professionals.

Danny Rischin, MD, reviews findings from the C-POST trial.

Patients with non–small cell lung cancer (NSCLC) had an objective response rate of about 77%.

Scott Tagawa, MD, professor of medicine and urology at Weill Cornell Medicine, discusses safety and tolerability findings observed to date, renal and hematologic considerations, and the role of pharmacists.

New research reveals similar severe outcomes for adults hospitalized with hMPV and RSV, emphasizing the need for awareness of both infections.

Pharmacists enhance LDL cholesterol management with tailored solutions like enlicitide, improving patient adherence and outcomes in cardiovascular care.

Giredestrant and everolimus show significant survival benefits for ER-positive, HER2-negative advanced breast cancer post-CDK4/6 therapy.

Discover how objective activity monitoring with accelerometers transforms cardiovascular risk assessment and treatment evaluation, enhancing patient care for pharmacists.

Expert highlights the benefits of early combination therapy in hypertension management, emphasizing improved blood pressure control and reduced side effects.

New research highlights the benefits of combining lutetium PSMA 617 with standard treatments, showing improved outcomes for prostate cancer patients.

Expert reveals ongoing disparities in heart valve disease care, stressing the need for improved diagnosis and treatment equity for vulnerable populations.

Boehringer Ingelheim showcases its commitment to cardio-kidney-metabolic research, highlighting innovative therapies and advancements at AHA 2025.

Discover how emerging therapies in cardio-kidney-metabolic health reshape disease management at AHA 2025, highlighting interconnected health pathways.

Integrating a pharmacist into multidisciplinary settings allowed for more thorough low-density lipoprotein cholesterol lowering in unique settings.

A new wrist-worn accelerometer device effectively monitors activity levels in heart failure patients, revealing critical insights into cardiovascular health.

Inclisiran significantly enhances LDL-C goal attainment in patients post acute coronary syndrome, improving lipid management outcomes.

New data from AHA 2025 demonstrate the benefits of pharmacist-led hypertension management in reducing hemoglobin A1c (HbA1c) and blood pressure in minority patients with type 2 diabetes.

Explore the critical role of pharmacists in improving cardiovascular health and addressing mortality trends in underserved communities.

A new drug, DR10624, shows promise in reducing triglycerides and liver fat, offering hope for patients with severe hypertriglyceridemia and fatty liver disease.

Shoa Clarke, MD, PhD, discusses the need for improved cholesterol testing and treatment in young adults, emphasizing the vital role of primary care teams and pharmacists in early intervention and adherence.

Explore the link between chronic kidney disease and cardiovascular risk, highlighting the importance of GFR and albuminuria in patient care.

Explore the need for integrated approaches in cardiovascular and kidney health to combat rising mortality rates and improve patient outcomes.

Experts at AHA 2025 advocate for integrated care in T2D and CKD, emphasizing cardiovascular risk management to enhance patient outcomes.